AQST Nov 2024 5.000 call
| Previous Close | 0.6000 |
| Open | 0.4200 |
| Bid | 0.4500 |
| Ask | 0.6000 |
| Strike | 5.00 |
| Expire Date | 2024-11-15 |
| Day's Range | 0.4200 - 0.5000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 1.34k |
GlobeNewswireAquestive Therapeutics to Report Third Quarter 2024 Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8:00 a.m. ET
WARREN, N.J., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the third quarter ended September 30, 2024 and provide an update on recent developments in its business after market close on Monday, November 4, 2024. Management will host a con
BenzingaOptimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate
On Friday, Aquestive Therapeutics, Inc. (NASDAQ:AQST) hosted a virtual investor day highlighting the company’s Anaphylm (epinephrine) Sublingual Film and AQST-108 (epinephrine) Topical Gel. Aquestive said it completed enrollment in its remaining supportive study for Anaphylm, the oral allergy syndrome (OAS) challenge study. Following the completion of dosing, the study is expected to be completed in the fourth quarter of 2024. The company remains on track to hold the FDA pre-New Drug Application
